Use of evidence‐based therapy and survival in heart failure in Sweden 2003–2012
Open Access
- 11 February 2016
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 18 (5), 503-511
- https://doi.org/10.1002/ejhf.496
Abstract
Aims In heart failure with reduced ejection fraction, drug and device therapy improve survival. We studied contemporary trends in utilization of evidence-based therapy and associated survival. Methods and results We studied 5908 patients with NYHA class II–IV heart failure, EF P-values for trends were as follows: renin–angiotensin system antagonists, 88% vs. 86% (P = 0.091); beta-blockers, 85% vs. 93% (P = 0.008); mineralocorticoid receptor antagonists, 53% vs. 42% (P < 0.001); CRT, 2.4% vs. 8.2% (P = 0.074); and implantable cardioverter-defibrillators, 4.0% vs. 10.7% (P = 0.004). During the same period, the risk-adjusted 30-day, 1-year, and 3-year survival was 92% vs. 94% (P = 0.532), 81% vs. 77% (P = 0.260), and 58% vs. 54% (P = 0.425), respectively. Conclusions In this large nationwide registry, over the last decade the use of evidence-based drug therapy was high and remained stable over time, but, despite an increased use of device therapy, the absolute use was poor. This was associated with an absence of improvement in survival. The improvements in therapy and prognosis over the last generation may be levelling off, and efforts should be directed at improving implementation of evidence-based therapy.Keywords
Funding Information
- Hjärt-Lungfonden (20080409, 20100419)
- Stockholms Läns Landsting (0055‐2009, 20110120)
This publication has 25 references indexed in Scilit:
- Association of Spironolactone Use With All-Cause Mortality in Heart FailureCirculation: Heart Failure, 2013
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Aliskiren, ALTITUDE, and the implications for ATMOSPHEREEuropean Journal of Heart Failure, 2012
- Incremental Reduction in Risk of Death Associated With Use of Guideline‐Recommended Therapies in Patients With Heart Failure: A Nested Case‐Control Analysis of IMPROVE HFJournal of the American Heart Association, 2012
- Get With The Guidelines Program Participation, Process of Care, and Outcome for Medicare Patients Hospitalized With Heart FailureCirculation: Cardiovascular Quality and Outcomes, 2012
- Comparison of Composite Measure Methodologies for Rewarding Quality of CareCirculation: Cardiovascular Quality and Outcomes, 2011
- Changing Characteristics and Mode of Death Associated With Chronic Heart Failure Caused by Left Ventricular Systolic DysfunctionCirculation: Heart Failure, 2011
- Eligibility Criteria of Randomized Controlled Trials Published in High-Impact General Medical JournalsJAMA, 2007
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureThe New England Journal of Medicine, 1999